EQ 101
Alternative Names: BNZ-1; BNZ132-1; BNZ132-1-40; EQ-101Latest Information Update: 14 Aug 2024
At a glance
- Originator Bioniz
- Developer Bioniz; Equillium
- Class Antineoplastics; Antivirals; Peptides; Skin disorder therapies
- Mechanism of Action Interleukin 15 inhibitors; Interleukin 15 receptor antagonists; Interleukin 2 inhibitors; Interleukin 2 receptor antagonists; Interleukin 9 inhibitors; Interleukin 9 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Cutaneous T-cell lymphoma
- Phase II Alopecia areata; Large granular lymphocytic leukaemia; T-cell leukaemia
- Research Vitiligo
- No development reported Adult T-cell leukaemia-lymphoma; Tropical spastic paraparesis
Most Recent Events
- 08 Aug 2024 Equillium plans a phase IIb trial for Alopecia areata in 2025 (SC)
- 04 Jun 2024 Updated efficacy and adverse event data from a phase II trial in Alopecia areata released by Equillium
- 30 Apr 2024 Equillium completes a phase II trial in Alopecia areata in Australia and New Zealand (IV) (NCT05589610)